Implementation of third-generation nanopore sequencing directed by CRISPR/Cas9 in HLA class I genes in pediatric neoplasms

Sequences obtained from a case of undifferentiated mucinous-type colon adenocarcinoma, which were obtained using different methodologies. The first sequence files correspond to sequences of PCR products targeting HLA class I genes (HLA-A, HLA-B, and HLA-C) compatible with the Illumina sequencing platform, corresponding to samples from tumor tissue, non-neoplastic tissue, and peripheral blood.Subsequently, the sequences correspond to those obtained using nanopore technology (Oxford Nanopore), enriched through the CRISPR/Cas9 system targeting HLA class I genes (HLA-A, HLA-B, and HLA-C), corresponding to tumor tissue, adjacent non-neoplastic tissue, and peripheral blood.Finally, exome sequences from the tumor tissue of the same case study are attached, which were obtained using the Illumina platform

本数据集包含来自1例未分化黏液型结肠腺癌病例的测序序列，所有序列通过多种不同实验方法获取。第一组序列文件为靶向人类白细胞抗原（HLA）I类基因（HLA-A、HLA-B及HLA-C）的PCR扩增产物测序序列，适配Illumina测序平台，对应的样本涵盖肿瘤组织、非肿瘤组织及外周血。后续序列采用纳米孔测序技术（Oxford Nanopore）获取，通过靶向HLA I类基因（HLA-A、HLA-B及HLA-C）的CRISPR/Cas9系统完成富集，对应的样本同样包括肿瘤组织、邻近非肿瘤组织及外周血。最后，本数据集附带该病例的肿瘤组织外显子组测序序列，该序列通过Illumina测序平台获取。